Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).

---

Wang M., Jurczak W., Jerkeman M., Trotman J., Zinzani P. L., Walewski J. A., ...Daha Fazla

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)

• Yayın Türü: Bildiri / Özet Bildiri
• Basıldığı Ülke: ELECTR NETWORK
• Ankara Üniversitesi Adresli: Evet